Skip to main content
Premium Trial:

Request an Annual Quote

InnoSign Raises $8M in Series A Financing, Spins off From Royal Philips

NEW YORK – Precision medicine company InnoSign announced on Tuesday that it has raised $8 million in a Series A financing. The proceeds will be used to finance the firm's spin off from Royal Philips to form a standalone company focused on its OncoSignal pathway activity profiling technology.

Investors in the financing round include Casdin Capital, Life Science Angels, Thuja Capital, and Brabant Development Agency. Philips owns a minority stake in the new company.

The investment enables InnoSign to leverage a first mover advantage and complete clinical validation studies prior to launch in the US market. InnoSign will be a US-based company but will maintain its research and development facility in Eindhoven, Netherlands.

The OncoSignal technology is a qPCR panel that tests for mRNA sequences associated with activity in diverse cancer-associated pathways. InnoSign's proprietary database has more than 100,000 pathway activity profiles and can be used for drug development and diagnostics to predict patient response to targeted therapies.

The firm's OncoSignal qPCR 7 pathway test is currently available for research use, according to a statement, and can be used on conventional PCR machines in combination with the OncoSignal cloud-based data analysis software.

Allan May, chair of Life Science Angels, said that limitations of DNA sequencing and protein analysis have become clear in recent years. "We believe InnoSign's proprietary mRNA-based signaling pathway tests, database with pathway activity profiles, and advanced analytics software will drive the next breakthroughs in precision medicine, initially in oncology, and then in other autoimmune and infectious disease."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.